Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332

Akeso Inc. and partner Summit Therapeutics announced updated, statistically significant overall survival (OS) data from the global Phase III HARMONi trial for ivonescimab, a novel PD-1/VEGF bispecific antibody. Longer-term follow-up of Western patients yielded an OS hazard ratio of 0.78 (p=0.0332), reinforcing previously established significant progression-free survival (PFS) benefits and demonstrating consistent efficacy across diverse global populations, including the HARMONi-A China study. These robust findings underscore ivonescimab's potential as a next-generation cancer therapy and support Akeso's dual-path strategy for global development and domestic commercialization.

Analysis

Akeso Inc. and its partner Summit Therapeutics have reported a significant clinical and regulatory milestone for their novel PD-1/VEGF bispecific antibody, ivonescimab. Updated analysis from the global Phase III HARMONi trial now demonstrates a statistically significant overall survival (OS) benefit, with a hazard ratio (HR) of 0.78 and a nominal p-value of 0.0332. This result addresses a key overhang from the primary analysis, which had shown a positive trend but failed to meet the prespecified p-value for statistical significance (p=0.057). The updated data, driven by longer follow-up in Western patients, shows particular strength in the North American cohort with an OS HR of 0.70. These findings are consistent with the already established, highly significant progression-free survival (PFS) benefit (HR 0.52; p<0.00001) and are corroborated by positive OS results from the parallel HARMONi-A trial in China. The drug's favorable safety profile and demonstrated efficacy against current standards of care, including pembrolizumab, in other head-to-head trials, position ivonescimab as a potentially best-in-class asset. This robust clinical evidence strongly supports Akeso's strategy of leveraging a vast development program across multiple cancer indications to maximize the drug's commercial value both in China and globally through its partnership with Summit Therapeutics.

Key Decisions for Investors

• The achievement of statistically significant Overall Survival represents a major de-risking event for ivonescimab, strengthening the investment case for both Akeso (9926.HK) and its global partner Summit Therapeutics (SMMT).
• Investors should monitor for upcoming regulatory filings with the FDA and other agencies, as the robust data package, especially the compelling OS hazard ratio of 0.70 in North American patients, significantly increases the probability of approval.
• The extensive pipeline, including eight additional registrational trials for ivonescimab in other major cancer types, should be viewed as a key long-term value driver, with further positive readouts poised to expand the drug's peak sales potential significantly.
• Given the demonstrated clinical benefits over established standards of care, investors should now model for a potentially accelerated market adoption and significant share capture for ivonescimab in the competitive non-small cell lung cancer market upon launch.